Placebo effect characteristics observed in a single, international, longitudinal study in Huntington’s disease.
Mov. Disord.. 2011-12-09; 27(3): 439-442
DOI: 10.1002/mds.24062
Lire sur PubMed
1. Mov Disord. 2012 Mar;27(3):439-42. doi: 10.1002/mds.24062. Epub 2011 Dec 9.
Placebo effect characteristics observed in a single, international, longitudinal
study in Huntington’s disease.
Cubo E(1), González M, del Puerto I, de Yébenes JG, Arconada OF, Gabriel y Galán
JM; European Huntington’s Disease Initiative Study Group.
Collaborators: Zangerl A, Seppi K, Wenning G, Poewe W, Foeldy D, Auff E, Schober
T, Wenzel K, Ott E, Walli J, Leblhuber F, Dürr A, Bloch F, Messouak O, Tallaksen
C, Dubois B, Guillamo JS, Bachoud-Lévi AC, Engles A, Krystkowiak P, Destée A,
Memin A, Thibaut-Tanchou S, Pasquier F, Azulay JP, Demonet JF, Galitzky M, Rascol
O, Mollion H, Broussolle E, Madigand M, Lallement F, Goizet C, Tison F,
Arguillère S, Viallet F, Bakchine S, Khoris J, Pages M, Camu W, Resch F,
Hannequin D, Durif F, Saudeau D, Autret A, Andrich J, Saft C, Kraus PH, Przuntek
H, Ecker D, Kramer B, Landwehrmeyer GB, Ludolph AC, Priller J, Meierkord H,
Kuznik D, Dose M, Squitieri F, Albanese A, Abbruzzese G, Filla A, van de
Warrenburg B, de Jong D, Kremer H, van Vugt J, Grimbergen Y, Roos R, Gawel M,
Janik P, Kowalczys H, Pilczuk B, Kwiecinski H, Świat M, Ochudło S, Modestowicz R,
Niezgoda A, łukasik M, Lukasik M, de Yébenes JG, García-Ruiz P, Descals AM, Rojo
A, Fontán A, Hernández J, Cantarero S, Fanjul S, Alegre J, Roldán SG, Mateo D,
Burguera JA, Solis P, Calopa M, Jaumà S, Bas J, Tolosa E, Muñoz JE, Gámez J,
Cervera C, Zarranz JJ, Lezcano E, Gómez JC, Chacón J, Dinca L, Gamero MA, Redondo
L, Castro A, Sesar A, López del Val J, López E, Ríos C, Castillio V, Burgunder
JM, Nirkko A, Kälin A, Vingerhoets F, Wider C.
Author information:
(1)Department of Neurology, Hospital General Yagüe, Burgos, Spain.
BACKGROUND: Classically, clinical trials are based on the placebo-control design.
Our aim was to analyze the placebo effect in Huntington’s disease.
METHODS: Placebo data were obtained from an international, longitudinal,
placebo-controlled trial for Huntington’s disease (European Huntington’s Disease
Initiative Study Group). One-hundred and eighty patients were evaluated using the
Unified Huntington Disease Rating Scale over 36 months. A placebo effect was
defined as an improvement of at least 50% over baseline scores in the Unified
Huntington Disease Rating Scale, and clinically relevant when at least 10% of the
population met it.
RESULTS: Only behavior showed a significant placebo effect, and the proportion of
the patients with placebo effect ranged from 16% (first visit) to 41% (last
visit). Nondepressed patients with better functional status were most likely to
be placebo-responders over time.
CONCLUSIONS: In Huntington’s disease, behavior seems to be more vulnerable to
placebo than overall motor function, cognition, and function
Copyright © 2011 Movement Disorder Society.
DOI: 10.1002/mds.24062
PMID: 22162184 [Indexed for MEDLINE]